Ganancias de Eli Lilly (LLY) en el cuarto trimestre de 4
Ganancias de Eli Lilly (LLY) en el cuarto trimestre de 4 Una pluma inyectable de Zepbound, el medicamento para bajar de peso de Eli Lilly, se exhibe en la ciudad de Nueva York, EE. UU., el 11 de diciembre de 2023. on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro. Zepbound, which won approval from U.S. regulators in early November, raked in $175.8 million in sales for the fourth quarter. The quarterly results are the first to include sales of Zepbound, which some analysts say could post more than a billion dollars in sales in its first year on the market and eventually, become the biggest drug of all time. Shares of Eli Lilly fell more than 1% on Tuesday following the results. The stock jumped almost 60% last year as weight loss drugs skyrocketed in popularity despite hefty price tags, mixed insurance coverage, a handful of unpleasant side effects and supply shortages. With a market cap of roughly $673 billion, Eli Lilly is the largest pharmaceutical company based in the U.S. Heres what Eli Lilly reported for the fourth quarter compared with what








